GlassScriptPhysician profile
Santiago Sanchez
NPI 1558037424
$5,073.47
in general payments reported to CMS, 2019-2025
27 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $142 · 2022: $2,669 · 2023: $1,759 · 2024: $323 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $949.52 | 2022-2025 | |
| Amgen INC. | $880.93 | 2022-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $450.50 | 2022-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $412.79 | 2022-2024 | Rybelsus, Ozempic, Saxenda |
| Lilly USA, LLC | $383.21 | 2022-2024 | Mounjaro, Baqsimi, Lyumjev |
| Currax Pharmaceuticals LLC | $314.70 | 2022-2023 | Contrave, Onzetra Xsail, Nexlizet |
| Astrazeneca Pharmaceuticals LP | $207.78 | 2022-2023 | Farxiga |
| Viiv Healthcare Company | $204.87 | 2022 | |
| Gilead Sciences, INC. | $188.33 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $174.39 | 2022-2023 | Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.85 | 2021-2022 | |
| Althera Pharmaceuticals LLC | $131.49 | 2021-2022 | |
| Exact Sciences Corporation | $104.27 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $86.90 | 2022 | |
| Novartis Pharmaceuticals Corporation | $51.01 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50.53 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.79 | 2023 | Xifaxan, Trulance |
| Abbott Laboratories | $48.10 | 2023 | Freestyle Libre 3 |
| Vital Connect, INC | $47.53 | 2022 | |
| Xeris Pharmaceuticals, INC. | $43.11 | 2024-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $25.92 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $25.54 | 2023 | Rexulti |
| Baxter Healthcare | $24.17 | 2023 | Hillrom - Microtymp 4 Portable Tympanometric Instrument |
| Sanofi-Aventis U.S. LLC | $22.64 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.83 | 2023 | |
| Dexcom, INC. | $15.95 | 2023 | Dexcom G6 Transmitter |
| Intuity Medical INC | $15.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santiago Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.